This article refers to:
The reference list in the above review article was published with elements missing; in particular, the journal titles in references 32, 33, 35 and 37. The corrected reference list is reproduced below.
References
- Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795
- Horning S J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–88
- McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
- Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–2642
- Cheson B D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101: 391–398
- Browman G P, Levine M N, Mohide E A, Hayward R S, Pritchard K I, Gafni A, et al. The practice guidelines development cycle: A conceptual tool for practice guidelines development and implantation. J Clin Oncol 1995; 13: 502–512
- Witzig T E, White C A, Wiseman G A, Gordon L I, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC – Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–3803
- Flinn I W, Kahl B S, Frey E, Bianco J A, Hammes R J, Billing L S, et al. Dose finding trial of Yttrium 90 (90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood 2004; 104(11)A897
- Fung H C, Forman S J, Nademanee A, Molina A, Yamauchi D, Speilberger R, et al. A new preparative regimen for older patients with aggressive CD 20-positive B-cell lymphoma utilizing standard-dose Yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplant-related toxicity [abstract]. Blood 2003; 102(11)A870
- Forero-Torres A, Besh S, Knox S, Micallef I, Wiseman G, Witzig T, et al. Higher doses of Rituxan alter pharmacokinetics and biodistribution of Zevalin but may increase responses; a preliminary report of a phase I study of Zevalin using a modified treatment regimen for relapsed or refractory CD20+ B-cell follicular/transformed non-Hodgkin's lymphoma [abstract]. Blood 2003; 102(11)A1483
- Sweetenham J W, Dicke K, Arcaroli J, Kogel K, Rana T M, Rice L L. Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma [abstract]. Blood 2004; 104(11)A2633
- Tsimberidou A M, Murray J L, O'Brien S, Wierda W G, Keating M J. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter Syndrome. Cancer 2004; 100: 2195–2200
- Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, et al. Randomized controlled trial of Yttrium-90 – labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
- Witzig T E, Flinn I W, Gordon L I, Emmanouilides C, Czuczman M S, Saleh M N, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
- Wiseman G A, Gordon L I, Multani P S, Witzig T E, Spies S, Bartlett N L, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 2002; 99: 4336–4342
- Knox S J, Goris M L, Trisler K, Negrin R, Davis T, Liles T M, et al. Yttrium-90-labelled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2: 457–470
- Morschhauser F, Huglo D, Martinelli G, Paganelli G, Zinzani P L, Hadjiyiannakis D, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial [abstract]. Blood 2004; 104(11)A130
- Oki Y, Pro B, Delpassand E, Ballaster V, McLaughlin P, Romaguera J, et al. A phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]. Blood 2004; 104(11)A2632
- Radford J A, Ketterer N, Sebban C, Zinzani P L, Delaloye A B, Rohatiner A, et al. Ibritumomab tiuxetan (Zevalin™) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: interim analysis for safety of a multicenter, phase III clinical trail [abstract]. Blood 2003; 102(11)A1484
- Liu N S, Keating M J, Albitar M, Wierda W G, Ferrajoli A, Tran N, et al. Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL [abstract]. Blood 2003; 102(11)A2498
- Shipley D L, Spigel D R, Carrell D L, Dannaher C, Greco F A, Hainsworth J D. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial [abstract]. J Clin Oncol 2004; 22(14 Suppl)A6519
- Witzig T E, Wiseman G A, Geyer S M, Cripe L, Inwards D J, Micallef I N, et al. A phase I trial of two-sequential doses of Zevalin™ radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma [abstract]. Blood 2003; 102(11)A1475
- Winter J N, Inwards D J, Spies S, Wiseman G, Patton D, Erwin W, et al. 90Y ibritumomab tiuxetan (Zevalin; 90YZ) doses higher than 0.4 mCi/kg may be safely combined with high-dose BEAM and autotransplant: the role for dosimetry [abstract]. Blood 2004; 104(11)A1162
- Nademanee A, Forman S J, Molina A, Kogut N, Fung H C, Yamauchi D, et al. High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): update of a phase I/II trial [abstract]. J Clin Oncol 2004; 22(14 Suppl)A6504
- Vose J M, Bierman P J, Lynch J C, Bociek G R, Multani P S, Armitage J O. Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT) [abstract]. Blood 2003; 102(11)A92
- Jacobs S A, McCook B, Torok F, Avril N, Vidnovic N, Joyce J, et al. Evaluation of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT) [abstract]. Blood 2004; 104(11)A5238
- Gordon L I, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5(2)98–101
- Gordon L I, Witzig T E, Murray J L, Czuczman M S, Emmanouilides C, Joyce R M, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular or transformed B-cell NHL: Final results of a randomized controlled trial [abstract]. Proc Am Soc Clin Oncol 2003; 22(576)A2315
- Wiseman G A, Witzig T E, Murray J L, Podoloff D A, Gordon L I, Schilder R J, et al. Zevalin radioimmunotherapy (RIT) improves quality of life (QOL) in patients with low grade, follicular, or transformed non-Hodgkin's lymphoma (LG/F/T NHL) [abstract]. Blood 2000; 96(11)A3173
- Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004; 19: 478–481
- Emmanouilides C, Czuczman M S, Revell S, Witzig T E, Wang H, Gordon L I, et al. Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan [abstract]. J Clin Oncol 2004; 22(14 Suppl)A6696
- Witzig T E, Gordon L I, Wiseman G A, Spies S, Emmanouilides C, Czuczman M S, et al. Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood 2000; 96(11)A3160
- Witzig T E, White C A, Gordon L I, Wiseman G A, Emmanouilides C, Murray J L, et al. Zevalin™ radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood 2001; 98(11)A2539
- Witzig T E, White C A, Gordon L I, Wiseman G A, Emmanouilides C, Murray J L, et al. Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263–1270
- Bartlett N L, Witzig T E, Gordon L, Beck T, Fehrenbacher L, Kornmehl E, et al. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients [abstract]. Proc Am Soc Clin Oncol 2002; 21(14a)A51
- Emmanouilides C, Murray J L, Vo K, Witzig T E, Darif M, Schilder R, et al. Earlier treatment with Yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL): results with second-line therapy [abstract]. Blood 2003; 102(11)A4949
- Czuczman M S, Emmanouilides C E, Witzig T, Gordon L, Murray J L, Ugoretz R, et al. Multivariate analysis of prognostic factors correlated with response to 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma [abstract]. Proc Am Soc Clin Oncol 2002; 21(266a)A1062
- Gibson A. Updated results of a phase III trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma. Clin Lymphoma 2002; 3: 87–89
- Nabhan C, Peterson L A, Kent S A, Tallman M S, Dewald G, Multani P, et al. Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43: 2145–2149
- Schilder R, Witzig T, Gordon L, Wiseman G, Murray J, Bartlett N, et al. Zevalin radioimmunotherapy (RIT) for low grade, follicular, and Cd20+ transformed non-Hodgkin's lymphoma (LG/F/T NHL) is effective even in patients with mild thrombocytopenia and poor prognostic factors [abstract]. Proc Am Soc Clin Oncol 2001; 20(236b)A2696
- Wiseman G A, Leigh B R, Dunn W L, Stabin M G, White C A. Additional radiation absorbed dose estimates for Zevalin™ radioimmunotherapy. Cancer Biother Radiopharm 2003; 18: 253–258
- Wiseman G A, White C A, Sparks R B, Erwin W D, Podoloff D A, Lamonica D, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trail of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 181–194
- Conti P, White C, Pieslor P, Menendez G, Harrough V D, Matso D, et al. Incidence of altered biodistribution detected by indium 111 (111In) imaging prior to yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy: results from a Zevalin imaging registry [abstract]. Blood 2004; 104(11)A4570